Related Experiment Video
Updated: Feb 17, 2026
06:08
A Novel Method: Super-selective Adrenal Venous Sampling
Published on: September 15, 2017
24.4K
Adrenocortical carcinoma: Single center experience
Pınar Şişman1, Ahmet Bilgehan Şahin2, Hande Peynirci3
1Clinic of Endocrinology and Metabolism, Harakani State Hospital, Kars, Turkey.
Turkish Journal of Urology
|December 5, 2017
Summary
Adrenocortical carcinoma has a poor prognosis, but adjuvant treatments, especially mitotane, significantly improve overall survival. Careful patient evaluation for surgical procedures and postoperative adjuvant therapy is crucial for better outcomes in this rare cancer.
Area of Science:
- Endocrinology
- Oncology
- Surgical Oncology
Background:
- Adrenocortical carcinoma is a rare and aggressive endocrine malignancy.
- Prognosis is primarily determined by tumor stage and surgical success.
- Factors like age, tumor size, and hormonal activity influence outcomes.
Purpose of the Study:
- To evaluate patient and treatment-related factors impacting adrenocortical carcinoma prognosis.
- To analyze the effect of various factors on disease-free and overall survival.
Main Methods:
- Retrospective analysis of 15 adrenocortical carcinoma patients (2005-2015).
- Evaluation of age, gender, tumor size, operation type, resection status, and adjuvant treatment effects.
- Analysis of disease-free survival and overall survival.
Main Results:
- Overall survival was 36.60±10.78 months; disease-free survival was 23.32±3.69 months.
- Tumor stage, size, hormonal activity, necrosis, recurrence, and metastasis did not significantly impact survival.
- Adjuvant treatments (mitotane, chemotherapy, radiotherapy) showed a significant increase in overall survival (p=0.006).
Conclusions:
- Adrenocortical carcinoma has a generally poor prognosis with frequent recurrence and metastasis.
- Surgical procedures and postoperative follow-up should be managed in experienced centers.
- Postoperative adjuvant treatments, particularly mitotane, should be considered to improve overall survival.
More Related Videos
Related Concept Videos
02:56Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
01:27Adrenal Gland Disorders
3.4K
Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
3.4K
02:49Cancer Therapies
10.2K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K